Unknown

Dataset Information

0

A cell-based assay for the detection of neutralizing antibodies against alemtuzumab.


ABSTRACT: Aim: The humanized anti-CD52 monoclonal antibody alemtuzumab depletes lymphocytes and is currently used to treat relapsing multiple sclerosis. During treatment, anti-alemtuzumab antibodies may develop and reduce effective lymphocyte depletion in future treatment cycles. Results: Alemtuzumab-Alexa Fluor 488 conjugate binding to the CHO-CD52 cell surface was inhibited by anti-alemtuzumab antibodies. Conclusion: In this proof-of-concept study, a CHO-CD52 cell line has been developed and used to detect the presence of anti-alemtuzumab neutralizing antibodies. This platform provides the basis of an assay for routine screening of serum for neutralizing antibodies from patients treated with alemtuzumab.

SUBMITTER: Ali L 

PROVIDER: S-EPMC7177201 | BioStudies | 2020-01-01

SECONDARY ACCESSION(S): AAH00644

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7443992 | BioStudies
2013-01-01 | S-EPMC3780590 | BioStudies
2013-01-01 | S-EPMC7122495 | BioStudies
2016-01-01 | S-EPMC4999148 | BioStudies
2015-01-01 | S-EPMC4403856 | BioStudies
1000-01-01 | S-EPMC5784003 | BioStudies
2012-01-01 | S-EPMC3382607 | BioStudies
2017-01-01 | S-EPMC5710323 | BioStudies
2013-01-01 | S-EPMC3807733 | BioStudies
2015-01-01 | S-EPMC4519957 | BioStudies